BR112022006250A2 - Compostos heterobicíclicos de arila como bloqueadores de canal de agitador de potássio kv1.3 - Google Patents
Compostos heterobicíclicos de arila como bloqueadores de canal de agitador de potássio kv1.3Info
- Publication number
- BR112022006250A2 BR112022006250A2 BR112022006250A BR112022006250A BR112022006250A2 BR 112022006250 A2 BR112022006250 A2 BR 112022006250A2 BR 112022006250 A BR112022006250 A BR 112022006250A BR 112022006250 A BR112022006250 A BR 112022006250A BR 112022006250 A2 BR112022006250 A2 BR 112022006250A2
- Authority
- BR
- Brazil
- Prior art keywords
- stirrer
- aryl
- potassium
- channel blockers
- heterobicyclic compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962911642P | 2019-10-07 | 2019-10-07 | |
| PCT/US2020/054348 WO2021071803A1 (en) | 2019-10-07 | 2020-10-06 | Aryl heterobicyclic compounds as kv1.3 potassium shaker channel blockers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022006250A2 true BR112022006250A2 (pt) | 2022-06-21 |
Family
ID=75436850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022006250A BR112022006250A2 (pt) | 2019-10-07 | 2020-10-06 | Compostos heterobicíclicos de arila como bloqueadores de canal de agitador de potássio kv1.3 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230040182A1 (https=) |
| EP (1) | EP4041408A4 (https=) |
| JP (1) | JP7780439B2 (https=) |
| KR (1) | KR20220079575A (https=) |
| CN (1) | CN114728177B (https=) |
| AU (1) | AU2020363354A1 (https=) |
| BR (1) | BR112022006250A2 (https=) |
| CA (1) | CA3156981C (https=) |
| IL (1) | IL291867A (https=) |
| MX (1) | MX2022004144A (https=) |
| WO (1) | WO2021071803A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2023003841A (es) | 2020-10-06 | 2023-06-23 | De Shaw Res Llc | Compuestos lactámicos como bloqueadores del canal agitador de potasio kv1.3. |
| CN114437070A (zh) * | 2022-01-19 | 2022-05-06 | 广西-东盟食品检验检测中心 | 一种他达拉非新型衍生物的制备方法 |
| WO2024088343A1 (zh) * | 2022-10-28 | 2024-05-02 | 上海深势唯思科技有限责任公司 | 一种芳基杂环类Kv1.3抑制剂及其制备方法和用途 |
| TW202521512A (zh) | 2023-07-31 | 2025-06-01 | 美商美國禮來大藥廠 | Kv1.3鉀shaker通道阻斷劑之固體形式及其使用方法 |
| WO2026021011A1 (zh) * | 2024-07-26 | 2026-01-29 | 浙江海正药业股份有限公司 | 芳基三环类衍生物及其制备方法和用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001007052A1 (en) * | 1999-07-21 | 2001-02-01 | Boehringer Ingelheim Pharmaceuticals, Inc. | Small molecules useful in the treatment of inflammatory disease |
| US6348486B1 (en) * | 2000-10-17 | 2002-02-19 | American Home Products Corporation | Methods for modulating bladder function |
| US6939968B2 (en) * | 2002-12-23 | 2005-09-06 | Bristol-Myers Squibb Company | Atropisomers of 3-substituted-4-arylquinolin-2-one derivatives |
| WO2005030729A1 (en) * | 2003-09-23 | 2005-04-07 | Merck & Co., Inc. | Isoquinoline potassium channel inhibitors |
| CN100530013C (zh) * | 2005-03-04 | 2009-08-19 | 松下电器产业株式会社 | 电子设备控制装置及其控制方法 |
| US7538110B2 (en) * | 2005-10-27 | 2009-05-26 | Adolor Corporation | Opioid antagonists |
| US8124636B2 (en) * | 2008-04-30 | 2012-02-28 | Hoffmann-La Roche Inc. | Imidazolidinone derivatives as 11B-HSD1 inhibitors |
| TW201026708A (en) * | 2008-12-12 | 2010-07-16 | Solvay Pharm Bv | Spiro azepane-oxazolidinones as Kv1.3 potassium channel blockers |
| WO2011073273A1 (en) * | 2009-12-16 | 2011-06-23 | Evotec Ag | Benzoxazine aryl sulfonamide derivatives as kv1.3 modulators |
| US20120065210A1 (en) * | 2010-09-15 | 2012-03-15 | Xin-Jie Chu | Substituted hexahydropyrrolo[1,2-c]imidazolones |
| TWI698438B (zh) * | 2015-03-13 | 2020-07-11 | 德商４Ｓｃ製藥公司 | Ｋv１.３抑制劑及其醫學應用 |
-
2020
- 2020-10-06 JP JP2022546588A patent/JP7780439B2/ja active Active
- 2020-10-06 MX MX2022004144A patent/MX2022004144A/es unknown
- 2020-10-06 US US17/766,837 patent/US20230040182A1/en active Pending
- 2020-10-06 EP EP20874328.6A patent/EP4041408A4/en active Pending
- 2020-10-06 IL IL291867A patent/IL291867A/en unknown
- 2020-10-06 BR BR112022006250A patent/BR112022006250A2/pt not_active IP Right Cessation
- 2020-10-06 AU AU2020363354A patent/AU2020363354A1/en not_active Abandoned
- 2020-10-06 KR KR1020227013493A patent/KR20220079575A/ko not_active Withdrawn
- 2020-10-06 CN CN202080084476.1A patent/CN114728177B/zh active Active
- 2020-10-06 CA CA3156981A patent/CA3156981C/en active Active
- 2020-10-06 WO PCT/US2020/054348 patent/WO2021071803A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP4041408A1 (en) | 2022-08-17 |
| CA3156981C (en) | 2025-06-17 |
| IL291867A (en) | 2022-06-01 |
| WO2021071803A1 (en) | 2021-04-15 |
| AU2020363354A1 (en) | 2022-04-21 |
| JP2022550641A (ja) | 2022-12-02 |
| JP7780439B2 (ja) | 2025-12-04 |
| KR20220079575A (ko) | 2022-06-13 |
| CA3156981A1 (en) | 2021-04-15 |
| US20230040182A1 (en) | 2023-02-09 |
| EP4041408A4 (en) | 2023-10-18 |
| MX2022004144A (es) | 2022-06-14 |
| CN114728177B (zh) | 2025-06-24 |
| CN114728177A (zh) | 2022-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022006202A2 (pt) | Compostos heterocíclicos de arila como bloqueadores de canal do agitador de potássio kv1,3 | |
| BR112022006250A2 (pt) | Compostos heterobicíclicos de arila como bloqueadores de canal de agitador de potássio kv1.3 | |
| BR112022006507A2 (pt) | Compostos heterocíclicos de arilmetileno como bloqueadores de canais de agitador de potássio kv1.3 | |
| BR112022006242A2 (pt) | Compostos aromáticos de arilmetileno como bloqueadores de canal do agitador de potássio kv1,3 | |
| SA522432955B1 (ar) | Kras g12c مثبطات | |
| MX2021009246A (es) | Inmunomoduladores, composiciones y metodos de los mismos. | |
| BR112021006229A2 (pt) | composto, composição farmacêutica, e, método para tratamento de um câncer | |
| CR20220251A (es) | Nuevos derivados de metilquinazolinona | |
| MX2020007265A (es) | Derivados de rapamicina. | |
| EA201892300A1 (ru) | Макроциклические ингибиторы mcl1 для лечения рака | |
| MX2021005714A (es) | Nuevos compuestos heterociclicos. | |
| MX2019004578A (es) | Oxisteroles y metodos de uso de los mismos. | |
| MX377277B (es) | Derivados de fenoximetilo. | |
| BR112017003658A2 (pt) | composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica. | |
| MX376833B (es) | Oxiesteroles y metodos de uso de los mismos. | |
| MX392270B (es) | Oxisteroles sustituidos en c7 y metodos de uso de los mismos. | |
| EA201991349A1 (ru) | Тетрациклические гетероциклические соединения, полезные в качестве ингибиторов интегразы вич | |
| MX2020010949A (es) | Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones viricas. | |
| CO2023004195A2 (es) | Compuestos heterocíclicos | |
| BR112021018578A2 (pt) | Compostos de heterociclil(fenil)metanol úteis no tratamento de hiperglicemia | |
| NZ746906A (en) | Oxaborole esters and uses thereof | |
| BR112022009058A2 (pt) | Compostos herbicidas | |
| BR112021026899A2 (pt) | Compostos heterocíclicos | |
| BR112022010871A2 (pt) | Composições farmacêuticas oftalmológicas | |
| BR112022006292A2 (pt) | Compostos heterobicílicos de arila como bloqueadores de canais de agitador de potássio kv1.3 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2848 DE 05-08-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |